Angus Rohan Chen

undignified, unfunny, unaward-winning journalist @STATNews. bylines: @wbur @npr @sciam @wnyc | English:Español:中文
BlueSky: angusrohan
signal: angus.08

[Angus Rohan Chen @angRchen]

HHS efficiency review blamed for delaying patient care at Indian Health Service https://t.co/2HFjMhd0yf via @statnews

[Jason Ukman @JasonUkman]

The small HHS office tasked with protecting clinical research participants’ safety has lost half its employees — through "reductions in force," resignations, or early retirements.

Via @MeganMolteni

https://t.co/PedqAQhL9K

[Steve Lee @steveleeyc]

Finally got our first #pancreaticcancer patient onto #daraxonrasib through @RevMedicines @FDAOncology Expanded Access Program. Turned into an unplanned bring-your-daughter-to-work day to get same-day consent to start therapy. Fingers crossed!

[Angus Rohan Chen @angRchen]

gahhh stop calling it granite, @ObamaFoundation Library media reviewers!! It. Is. GNEISSSSSSS!!!!!! Geologists of twitter back me up here

[Angus Rohan Chen @angRchen]

Congratulations @ollywainwright on this laugh out loud review of the Obama center.
https://t.co/b0rtwzohcY

But I think this center isn't walls of granite. Having visited after ASCO, the pattern and texture of the material looks much more like gneiss

[Angus Rohan Chen @angRchen]

@PhilipKennicott

[Angus Rohan Chen @angRchen]

Congratulations @ollywainwright on this laugh out loud review of the Obama center.
https://t.co/b0rtwzohcY

But I think this center isn't walls of granite. Having visited after ASCO, the pattern and texture of the material looks much more like gneiss

[Angus Rohan Chen @angRchen]

As a metaphor, this metamorphic rock may be just what the Obama designers wanted to convey. Something that reflects transformation and maintains the visual aspect of movement and life in its final state. So that's interesting, I guess, from a totally speculative standpoint

[Parker Institute for Cancer Immunotherapy @parkerici]

PICI CEO @DrKarenKnudsen joined @statnews' Science vs. Cancer event at ASCO this past weekend, alongside @DrRoyHerbst, Ensign Professor of Medicine and Chief of Medical Oncology and Hematology at @YaleMed and STAT News cancer reporter @angRchen.

The discussion explored key themes from ASCO, including the most significant developments in oncology and what lies ahead for the future of cancer research.

Thank you @statnews for bringing together an insightful conversation and including PICI in the discussion.

Read more on the event: https://t.co/FGuaP53vAq

[Angus Rohan Chen @angRchen]

Anyway. I'll stop talking about rocks and go back to writing about cancer. I did just read the Obama center used "Tapestry granite" which is actually gneiss. So remember these key takeaways: don't take schist for granite. I lava gneiss geologist. and orogeny is a real word.

[Angus Rohan Chen @angRchen]

To call it granite is also interesting in a made up way. Granite is made by a hunk of once blazing hot magma slowly losing vigor until it freezes deep underground. maybe the feeling that some visitors get from the "obamalisk" judging by this review?

[Dana-Farber @DanaFarber]

A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer.

In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy.

While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers.

As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.”

Congratulations to the researchers and patients who made this important progress possible. 👏👏👏

Video Courtesy: @asco

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Jason Ukman @JasonUkman]

NEW: From Revolution Medicines, more strong data on pancreatic cancer drug and a glimpse of a ‘novel class’ beyond it. Via @angRchen @statnews

https://t.co/urRF6Pwu8J

[Anirban Maitra @Aiims1742]

Ok folks @angRchen @statnews has written THE story of KRAS inhibitors featuring the greatest players and the historical timeline leading to where we are today. This is a must read!
@GregVerdinne @kevansf @cjder23 @andrewaguirremd @EileenMOReilly
#AACR26
https://t.co/sBHiXGueIU

[Jonathan Wosen, Ph.D. @JonathanWosen]

Interviews with 30 researchers who responded to a nationwide @statnews survey on the impacts of federal science policy brought the human toll of changes at NIH into sharp focus. @AnilOza16 and I bring you 3 of those stories. 👇
https://t.co/OIH0FoNrsm

[Angus Rohan Chen @angRchen]

@rachelcohrs really scary!! i'm very relieved to see you're doing okay and on the way to a full recovery. hugs from all of us at stat

[Elad Sharon @EladSharonMD]

Feels like we are winning today… the editors have to give the authors a chance to respond. And, frankly, I will be interested in the response…

[Lizzy Lawrence @LizzyLaw_]

Honored to have won a George Polk award for my coverage of the turmoil at FDA last year. The STAT team was also recognized for reporting on the Trump admin's impact on health and science. https://t.co/D3bp4J5xrr

[Bob Herman @bobjherman]

Multi-cancer early detection tests cost as much as $950. They aren't FDA-approved. There's no evidence they are beneficial for patients. And yet, Hims is advertising them in a Super Bowl ad. Read more from @KatieMPalmer: https://t.co/48ecFNspaK